#FirstofItsKind Parkinson's biomarker guidelines invigorates
A slate of guidelines to shape the future of Parkinson's biomarker research have been published in the journal Science Translational Medicine. While previous recommendations have been created to support the research of Parkinson's biomarkers, this is the first developed in collaboration with institutions outside of academic medicine, including The Michael J. Fox Foundation for Parkinson's Research.

The guidelines focus on three areas--recommendations for types of biomarkers researchers should identify in order to aid the development of new treatments, resources for collaboration, and research principles to follow.

Previous research efforts have largely focused on biomarkers that distinguish Parkinson's disease from healthy individuals or those with other neurodegenerative diseases such as Alzheimer's disease.

However, these guidelines argue for a shift to focus on biomarkers that look within Parkinson's disease itself, as there are many ways the disease manifests in patients. This is an important element for planning clinical trials and developing new treatments.

Researchers have already built an ecosystem of biobanks at different centers across the world, which hold thousands of biological samples including blood and tissue. These biobanks hold many clues that could help propel the next breakthroughs in the treatment of neurodegenerative diseases, and the guidelines list recommended biobanks as a resource for researcher collaborations.

The guidelines also include recommendations for biomarker research standards, such as larger sample sizes and replication across multiple patient groups. These principles will harmonize findings, streamlining and advancing the biomarker discovery process.

Read more here: https://www.pennmedicine.org/news/news-releases/2018/august/first-of-its-kind-parkinsons-disease-biomarker-guidelines-invigorates-drive-for-treatments